Aliskiren: new contraindication and warning.(Safety and Efficacy Issues)(Brief article)

European Union -- The European Medicines Agency (EMEA) has recommended adding a contraindication to the product information for aliskiren, stating that it must not be used in patients who have experienced angioedema when taking aliskiren in the past. The Agency also recommended the inclusion of a warning, stating that patients who develop signs of angioedema should stop treatment and seek medical attention.

Aliskiren, a renin inhibitor, is authorized for the treatment of essential hypertension. It has been authorized in …